Literature DB >> 30034933

Cancer in a dish: progress using stem cells as a platform for cancer research.

Mo Liu1, Jian Tu1,2, Julian A Gingold3, Celine Shuet Lin Kong1, Dung-Fang Lee1,4,5,6.   

Abstract

Cancer models derived from patient specimens poorly reflect early-stage cancer development because cancer cells acquire numerous additional molecular alterations before the disease is clinically detectable. Earlier studies have used differentiated cells derived from induced pluripotent cancer cells (iPCCs) to partially mirror cancer disease phenotype, but the highly heterogeneous nature of cancer cells as well as difficulties with reprogramming cancer cells has limited the application of this technique. An alternative approach to modeling cancer in a dish entails reprogramming adult differentiated cells from patients with cancer syndromes to pluripotent stem cells (PSCs), followed by directed differentiation of those PSCs. A directed reprogramming and differentiation strategy has the potential to recapitulate cancer progression and capture the earliest molecular alterations that underlie cancer initiation. The reprogrammed cells share patient-specific genetic and epigenetic traits, offering a new platform to develop personalized therapy for cancer patients. In this review, we will provide an overview of available reprogramming methods of cancer cells and describe how cancer-derived stem cells have been used to characterize effects of defined molecular alterations in specific cell types. We also describe the "disease in a dish" model developed to study genetic cancer syndromes. These approaches highlight recent contributions of stem cell technology to the cancer biology realm.

Entities:  

Keywords:  Disease model; induced pluripotent cancer cells; induced pluripotent stem cells; reprogramming

Year:  2018        PMID: 30034933      PMCID: PMC6048395     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  64 in total

1.  Tumor-homing cytotoxic human induced neural stem cells for cancer therapy.

Authors:  Juli R Bagó; Onyi Okolie; Raluca Dumitru; Matthew G Ewend; Joel S Parker; Ryan Vander Werff; T Michael Underhill; Ralf S Schmid; C Ryan Miller; Shawn D Hingtgen
Journal:  Sci Transl Med       Date:  2017-02-01       Impact factor: 17.956

Review 2.  Osteosarcoma: Molecular Pathogenesis and iPSC Modeling.

Authors:  Yu-Hsuan Lin; Brittany E Jewell; Julian Gingold; Linchao Lu; Ruiying Zhao; Lisa L Wang; Dung-Fang Lee
Journal:  Trends Mol Med       Date:  2017-07-20       Impact factor: 11.951

3.  Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia.

Authors:  W J Song; M G Sullivan; R D Legare; S Hutchings; X Tan; D Kufrin; J Ratajczak; I C Resende; C Haworth; R Hock; M Loh; C Felix; D C Roy; L Busque; D Kurnit; C Willman; A M Gewirtz; N A Speck; J H Bushweller; F P Li; K Gardiner; M Poncz; J M Maris; D G Gilliland
Journal:  Nat Genet       Date:  1999-10       Impact factor: 38.330

4.  Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia.

Authors:  Andriana G Kotini; Chan-Jung Chang; Arthur Chow; Han Yuan; Tzu-Chieh Ho; Tiansu Wang; Shailee Vora; Alexander Solovyov; Chrystel Husser; Malgorzata Olszewska; Julie Teruya-Feldstein; Deepak Perumal; Virginia M Klimek; Alexandros Spyridonidis; Raajit K Rampal; Lewis Silverman; E Premkumar Reddy; Elli Papaemmanuil; Samir Parekh; Benjamin D Greenbaum; Christina S Leslie; Michael G Kharas; Eirini P Papapetrou
Journal:  Cell Stem Cell       Date:  2017-02-16       Impact factor: 24.633

5.  Modeling familial Alzheimer's disease with induced pluripotent stem cells.

Authors:  Takuya Yagi; Daisuke Ito; Yohei Okada; Wado Akamatsu; Yoshihiro Nihei; Takahito Yoshizaki; Shinya Yamanaka; Hideyuki Okano; Norihiro Suzuki
Journal:  Hum Mol Genet       Date:  2011-09-07       Impact factor: 6.150

Review 6.  Modeling Cancer with Pluripotent Stem Cells.

Authors:  Julian Gingold; Ruoji Zhou; Ihor R Lemischka; Dung-Fang Lee
Journal:  Trends Cancer       Date:  2016-08-21

Review 7.  Stem cell contributions to neurological disease modeling and personalized medicine.

Authors:  Nicholas Liang; Cleber A Trujillo; Priscilla D Negraes; Alysson R Muotri; Claudiana Lameu; Henning Ulrich
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2017-05-31       Impact factor: 5.067

8.  Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells.

Authors:  Kosuke Yusa; S Tamir Rashid; Helene Strick-Marchand; Ignacio Varela; Pei-Qi Liu; David E Paschon; Elena Miranda; Adriana Ordóñez; Nicholas R F Hannan; Foad J Rouhani; Sylvie Darche; Graeme Alexander; Stefan J Marciniak; Noemi Fusaki; Mamoru Hasegawa; Michael C Holmes; James P Di Santo; David A Lomas; Allan Bradley; Ludovic Vallier
Journal:  Nature       Date:  2011-10-12       Impact factor: 49.962

9.  Therapeutically engineered induced neural stem cells are tumour-homing and inhibit progression of glioblastoma.

Authors:  Juli R Bagó; Adolfo Alfonso-Pecchio; Onyi Okolie; Raluca Dumitru; Amanda Rinkenbaugh; Albert S Baldwin; C Ryan Miller; Scott T Magness; Shawn D Hingtgen
Journal:  Nat Commun       Date:  2016-02-02       Impact factor: 14.919

10.  Generation of human embryonic stem cell line with heterozygous RB1 deletion by CRIPSR/Cas9 nickase.

Authors:  Jian Tu; Zijun Huo; Mo Liu; Donghui Wang; An Xu; Ruoji Zhou; Dandan Zhu; Julian Gingold; Jingnan Shen; Ruiying Zhao; Dung-Fang Lee
Journal:  Stem Cell Res       Date:  2018-02-28       Impact factor: 2.020

View more
  5 in total

1.  Cancer Stem Cells in Tumor Modeling: Challenges and Future Directions.

Authors:  Elvan Dogan; Asli Kisim; Gizem Bati-Ayaz; Gregory J Kubicek; Devrim Pesen-Okvur; Amir K Miri
Journal:  Adv Nanobiomed Res       Date:  2021-06-23

Review 2.  Emerging agents that target signaling pathways in cancer stem cells.

Authors:  Yue Yang; Xiaoman Li; Ting Wang; Qianqian Guo; Tao Xi; Lufeng Zheng
Journal:  J Hematol Oncol       Date:  2020-05-26       Impact factor: 17.388

Review 3.  Ten years of research on the role of BVES/ POPDC1 in human disease: a review.

Authors:  Ping Han; Yu Lei; Dongxiao Li; Jingmei Liu; Wei Yan; Dean Tian
Journal:  Onco Targets Ther       Date:  2019-02-18       Impact factor: 4.147

Review 4.  Cellular Reprogramming-A Model for Melanoma Cellular Plasticity.

Authors:  Karol Granados; Juliane Poelchen; Daniel Novak; Jochen Utikal
Journal:  Int J Mol Sci       Date:  2020-11-05       Impact factor: 5.923

5.  Patient-derived iPSCs link elevated mitochondrial respiratory complex I function to osteosarcoma in Rothmund-Thomson syndrome.

Authors:  Brittany E Jewell; An Xu; Dandan Zhu; Mo-Fan Huang; Linchao Lu; Mo Liu; Erica L Underwood; Jun Hyoung Park; Huihui Fan; Julian A Gingold; Ruoji Zhou; Jian Tu; Zijun Huo; Ying Liu; Weidong Jin; Yi-Hung Chen; Yitian Xu; Shu-Hsia Chen; Nino Rainusso; Nathaniel K Berg; Danielle A Bazer; Christopher Vellano; Philip Jones; Holger K Eltzschig; Zhongming Zhao; Benny Abraham Kaipparettu; Ruiying Zhao; Lisa L Wang; Dung-Fang Lee
Journal:  PLoS Genet       Date:  2021-12-29       Impact factor: 6.020

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.